The evaluated GLP-1RAs were semaglutide (IC 025 = 2.13), liraglutide (IC 025 = 1.18), dulaglutide (IC 025 = 3.76), exenatide (IC 025 = 3.52), and albiglutide (IC 025 = 3.91), none of which exhibited a signal of disproportionate reporting
Several developments could reshape pricing and availability in 2026 and beyond: Shortage list changes
A non-peptide structure reduces enzymatic degradation concerns and simplifies stability considerations in research workflows
For each medication cohort, the use of other drugs of interest (i.e., SGLT2i, ACEi/ARB, GLP-1 RA, steroidal MRA [sMRA]) relative to the index medication was classified into three distinct time periods relative to the index date: within 90 days before, on, and within 90 days after, respectively